Article
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
The New England journal of medicine - 13 Nov 2014
Larkin James, Ascierto Paolo A, Dréno Brigitte, Atkinson Victoria, Liszkay Gabriella, Maio Michele, Mandalà Mario, Demidov Lev, Stroyakovskiy Daniil, Thomas Luc, de la Cruz-Merino Luis, Dutriaux Caroline, Garbe Claus, Sovak Mika A, Chang Ilsung, Choong Nicholas, Hack Stephen P, McArthur Grant A, Ribas Antoni
Abstract excerpt
BACKGROUND: The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. METHODS: We randomly assigned 495 patients with previously untreated unresectable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.